Thermo Fisher Scientific Inc. (TMO) Stock Price & Analysis
Thermo Fisher Scientific Inc. (TMO) fell 0.75% to USD 613.78 as of September 8, 2026 at 02:49 UTC, according to Nexqual real-time market data.
TMO last closed at USD 618.43; the session ranged USD 605.53–615.58 on volume of 1,216,225 shares. Market capitalization is $226.94B, with a 52-week range of USD 435.27–647 (NYQ). Source: Nexqual, September 8, 2026 at 02:49 UTC.
Key Statistics (as of September 8, 2026 at 02:49 UTC)
| Price | USD 613.78 |
|---|---|
| Change | ▼ 0.75% (down) |
| Previous Close | USD 618.43 |
| Open | USD 608.58 |
| Day Range | USD 605.53 – 615.58 |
| 52-Week Range | USD 435.27 – 647 |
| Volume | 1,216,225 shares |
| Market Cap | $226.94B |
| Exchange | NYQ |
Technical Analysis (TMO)
Nexqual's technical model rates TMO "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 02:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.13 (neutral) |
| vs SMA50 | Above (USD 570.73) |
| MACD | 13.19 (positive) |
Analyst Ratings (TMO)
Wall Street analysts rate TMO "Buy" based on 27 analysts, with a mean price target of USD 638.11 (range USD 520–750), per Nexqual as of September 8, 2026 at 02:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 27 |
| Mean Target | USD 638.11 |
| High Target | USD 750 |
| Low Target | USD 520 |
| Buy / Hold / Sell | 23 / 5 / 1 |
Earnings (TMO)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 6.4 |
| Revenue Estimate | $11.95B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 6.03 vs est 5.71 ▲ beat |
| 2026-03-31 | USD 5.44 vs est 5.24 ▲ beat |
| 2025-12-31 | USD 6.57 vs est 6.45 ▲ beat |
| 2025-09-30 | USD 5.79 vs est 5.5 ▲ beat |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Financials & Fundamentals (TMO)
| Total Revenue | $46.34B |
|---|---|
| Revenue Growth (YoY) | +10.50% |
| Gross Margin | +40.99% |
| Operating Margin | +18.75% |
| Profit Margin | +15.04% |
| ROE | +13.51% |
| Debt / Equity | 80.58 |
| Current Ratio | 1.55 |
| Total Cash | $4.06B |
| Total Debt | $42.55B |
| Free Cash Flow | $6.24B |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Financial Health Score (TMO)
Nexqual rates Thermo Fisher Scientific Inc.'s overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 02:49 UTC.
| Growth | Mixed — Revenue +3.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 19% |
| Balance Sheet | Mixed — $4.06B cash vs $42.5B debt |
| Cash Flow | Solid — FCF $6.24B, 14% margin |
| Efficiency | Mixed — ROE 14%, ROA 5.1% |
Ownership (TMO)
| Insider Ownership | +0.13% |
|---|---|
| Institutional Ownership | +94.19% |
| Shares Outstanding | 369.75M |
| Float | 368.82M |
| Short % of Float | +1.28% |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
Leadership (TMO)
Thermo Fisher Scientific Inc. is led by Marc N. Casper (age 57), Chairman & CEO, per Nexqual as of September 8, 2026 at 02:49 UTC.
| Chairman & CEO | Marc N. Casper (age 57) |
|---|---|
| President, COO & President of Products and Technologies | Gianluca Pettiti (age 46) |
| Senior VP & CFO | James R. Meyer (age 45) |
| Chief Scientific Officer | Karen E. Nelson |
| Vice President of Investor Relations | Rafael Tejada |
Major Backers & Investors (TMO)
Notable institutional backers of Thermo Fisher Scientific Inc. include FMR, LLC, Morgan Stanley, Fidelity, according to Nexqual as of September 8, 2026 at 02:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 3.81% |
| Morgan Stanley | 2.91% |
| Fidelity | 2.36% |
| JPMorgan | 2.3% |
| Franklin Resources, Inc. | 1.97% |
| Capital Group | 1.68% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.55% |
| BlackRock | 9.74% |
| State Street | 5.79% |
| Geode Capital | 2.27% |
Source: Nexqual, September 8, 2026 at 02:49 UTC.
From Thermo Fisher Scientific Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Department of Health and Human Services (the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws and regulations could adversely affect us.
- We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business.
- Patents may not be issued for any pending or future patent applications owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology.
- In addition, competitors may design around our technology or develop competing technologies.
Partnerships
- In addition, we have availability to borrow under a revolving credit facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility).
- On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion the company's common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DHR | Danaher Corporation | USD 207.66 | ▼ 1.07% |
| SYK | Stryker Corporation | USD 303.13 | ▼ 2.9% |
| ZTS | Zoetis Inc. | USD 75.81 | ▼ 0.47% |
| BDX | Becton, Dickinson and Company | USD 184.74 | ▼ 1.48% |
| ISRG | Intuitive Surgical, Inc. | USD 366.7 | ▼ 1.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:49 UTC. This page is informational and not investment advice.